Teclistamab (Tecvayli®). HTA ID: 22064

Assessment Status NCPE assessment ongoing
HTA ID 22064
Drug Teclistamab
Brand Tecvayli®
Indication As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 20/09/2022
Rapid review completed 03/11/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teclistamab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/11/2022
Pre-submission consultation with Applicant 24/01/2023
Full submission received from Applicant 18/05/2023
Preliminary review sent to Applicant 06/02/2024
NCPE assessment re-commenced 07/03/2024